Reshape Lifesciences (Reshape Lifesciences) Cash-to-Debt : 17.02 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Reshape Lifesciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Reshape Lifesciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 17.02.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Reshape Lifesciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Reshape Lifesciences's Cash-to-Debt or its related term are showing as below:

RSLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22 Med: 19.78 Max: No Debt
Current: 17.02

During the past 13 years, Reshape Lifesciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.22. And the median was 19.78.

RSLS's Cash-to-Debt is ranked better than
77.61% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs RSLS: 17.02

Reshape Lifesciences Cash-to-Debt Historical Data

The historical data trend for Reshape Lifesciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Reshape Lifesciences Cash-to-Debt Chart

Reshape Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.82

0.22

81.60

22.54

17.02

Reshape Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															22.54	104.45	14.88	5.08	17.02

Competitive Comparison of Reshape Lifesciences's Cash-to-Debt

For the Medical Devices subindustry, Reshape Lifesciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reshape Lifesciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Cash-to-Debt falls into.

Reshape Lifesciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Reshape Lifesciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.459	/	(0.111	+	0.151)
	=	17.02

Reshape Lifesciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.459	/	(0.111	+	0.151)
	=	17.02

Reshape Lifesciences (OTCPK:RSLS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Reshape Lifesciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Reshape Lifesciences (Reshape Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (OTCPK:RSLS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RSLS:USA

Address

1001 Calle Amanecer, San Clemente, CA, USA, 92673

Website

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Executives

Thomas Stankovich	officer: Chief Financial Officer	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Barton P. Bandy	officer: President and CEO	1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Dan W Gladney	director, officer: Chairman, President and CEO	2800 PATTON ROAD, ST. PAUL MN 55113
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Sabby Management, Llc	10 percent owner	115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Arda Phd Minocherhomjee	director	C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Scott P Youngstrom	officer: CFO and SVP, Finance	2800 PATTON ROAD ST. PAUL MN 55113
Joseph Patrick Healey	10 percent owner	31 HUDSON YARDS, 10TH FLOOR, NEW YORK NY 10001
Healthcor Partners Ii, L.p.	10 percent owner	152 W. 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Michael Y Mashaal	director	309 WAVERLEY OAKS RD., SUITE 105 WALTHAM MA 02452
Healthcor Partners Fund Ii, L.p.	10 percent owner	CARNEGIE HILL TOWER 152 WEST 57TH STREET, 43RD FLOOR NEW YORK NY 10019
Jeffrey C Lightcap	10 percent owner	152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019
Healthcor Partners Management Gp, Llc	10 percent owner	152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019